Subgroup analyses of phase II study of weekly paclitaxel in advanced esophageal cancer that had previously received docetaxel-containing chemotherapy

We conducted a phase II trial of weekly paclitaxel (wPTX) in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy. Although primary end point was unmet (confirmed objective response rate (ORR) was 0%), wPTX showed modest efficacy, DCR, mPFS and mOS were 52% 81 days, and 211 days, respectively. We examined efficacy by previous docetaxel regimen, DCF (docetaxel, cisplatin and 5-fluorouracil) vs docetaxel alone in this subgroup analysis.